Ascendis Pharma A (ASND) Other Operating Expenses (2018 - 2026)

Ascendis Pharma A has reported Other Operating Expenses for 8 years, with the latest figure at $138.5 million in Q4 2025.

• Quarterly Other Operating Expenses changed N/A year-over-year to $138.5 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $138.5 million (changed N/A YoY) and the FY2025 annual result came in at -$997.0 million, down 1025158.24% from the prior year.
• Other Operating Expenses rose to $138.5 million in Q4 2025 per ASND's latest filing, from -$98858.9 in the prior quarter.
• Over five years, Other Operating Expenses peaked at $138.5 million in Q4 2025 and troughed at -$262.9 million in Q4 2021.
• A 5-year average of -$15.6 million and a median of $6722.9 in 2022 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2021 and 2024: Other Operating Expenses surged 66.02% in 2021, then sank 538.59% in 2024.
• Over 5 years, Other Operating Expenses stood at -$262.9 million in 2021, then jumped by 100.0% to $8066.2 in 2022, then plunged by 33.31% to $5379.7 in 2023, then plunged by 1937.63% to -$98858.9 in 2024, then jumped by 140233.01% to $138.5 million in 2025.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $138.5 million, -$98858.9, and $5379.7 for Q4 2025, Q1 2024, and Q4 2023 respectively.